Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.30
-0.16 (-2.48%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
1,8101,507355331141448
Upgrade
Market Cap Growth
654.54%324.92%7.14%134.50%-68.52%-55.28%
Upgrade
Enterprise Value
1,5611,278260227170314
Upgrade
Last Close Price
6.305.501.731.772.2611.65
Upgrade
PS Ratio
185.23154.1642.5521.4256.40-
Upgrade
PB Ratio
7.276.104.964.42148.704.70
Upgrade
P/TBV Ratio
7.336.104.964.42148.704.70
Upgrade
EV/Sales Ratio
159.69130.8031.1914.6767.98-
Upgrade
Debt / Equity Ratio
0.280.280.880.8263.150.66
Upgrade
Net Debt / Equity Ratio
-1.01-1.01-1.06-1.10-29.45-0.90
Upgrade
Net Debt / EBITDA Ratio
2.282.280.891.180.220.50
Upgrade
Net Debt / FCF Ratio
2.662.660.931.080.260.65
Upgrade
Asset Turnover
0.040.040.050.100.02-
Upgrade
Quick Ratio
12.0412.045.303.921.402.88
Upgrade
Current Ratio
12.2312.235.424.081.543.08
Upgrade
Return on Equity (ROE)
-68.45%-68.45%-121.94%-294.04%-344.67%-100.68%
Upgrade
Return on Assets (ROA)
-27.42%-27.42%-32.51%-29.84%-46.30%-45.80%
Upgrade
Return on Capital Employed (ROCE)
-34.90%-34.90%-64.60%-52.50%-198.50%-106.80%
Upgrade
Earnings Yield
-6.02%-7.23%-25.19%-33.71%-117.64%-38.94%
Upgrade
FCF Yield
-5.18%-6.23%-23.02%-23.23%-77.25%-29.53%
Upgrade
Buyback Yield / Dilution
-27.82%-27.82%-115.41%-164.20%-16.74%-113.13%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.